Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Functional consequences of ADK
2024-04-07

Functional consequences of ADK regulation on astrocyte function As outlined above (see introduction), ADK critically regulates the extracellular adenosine levels in BKT140 australia (Boison, 2006, Etherington et al., 2009). Changes in the levels of adenosine, as a result of the regulation of ADK
-
The discovery of acetylsalicylic acid
2024-04-03

The discovery of acetylsalicylic enos inhibitor (aspirin) in 1897 paved the way for the development of classical NSAIDs as first-line therapeutics for anti-inflammatory, anti-pyretic and analgesic therapy. Large efforts have been made in the following decades to improve the efficacy and in particul
-
br Results and discussion br Conclusions In this report
2024-04-03

Results and discussion Conclusions In this report we present the synthesis, structure determination, and the in vitro and in vivo evaluation of a series of new quinone analogues aiming to find novel lead structures for the development of 5-LO inhibitors. Our findings support that also the hydr
-
br Disclosure statement br Acknowledgements The work was
2024-04-03

Disclosure statement Acknowledgements The work was supported by the National Science Foundation of China (Nos. 81273526, 81473268) and Natural Science Foundation of Colleges and Universities (Nos. KJ2017A197). What is already known What this article adds Introduction Sevoflurane is
-
Stroke also known as a cerebrovascular accident or
2024-04-03

Stroke, also known as a cerebrovascular accident or Nitecapone receptor attack, is one of the leading causes of death and disability worldwide (Haley et al., 2017; Hankey, 2017; Lie et al., 2017). According to the data released by the World Health Organization (WHO), stroke occurs every 5 s worldwid
-
ATP citrate lyase ACLY is
2024-04-03

ATP citrate lyase (ACLY) is a cytosolic enzyme that catalyzes the generation of acetyl-CoA from citrate [15]. Acetyl-CoA is the building block for the biosynthesis of fatty acids and cholesterol, and also serves as a substrate of the acetylation reaction of various molecules, including histones and
-
The most likely explanation for
2024-04-03

The most likely explanation for the species differences in aromatase distribution and the unique Zoniporide dihydrochloride distribution in humans is the unique location, size and highly elaborate organization of the human aromatase gene (e.g. Bulun et al., 2003). The human Cyp19 is a large gene lo
-
PRT 4165 Another major problem leading to
2024-04-03

Another major problem leading to implant failures is post-implant infections, majorly due to bacteria adhesion [13,36,37]. A significant decrease in bacterial counts (~65–90%) has been observed in HA and/or CNT-based composites reinforced with 2.5–10 wt% nano Ag [13,38], thus, drawing the conclusion
-
Despite the absence of disulfide bonds in its linear structu
2024-04-03

Despite the absence of disulfide bonds in its linear structure, KT43C displays antifungal and antibacterial activity. Disulfide bonds are determinants of defensins' integrity and have been reported to increase the antimicrobial activity (Jenssen et al., 2006). However, some linear derivatives of AMP
-
Linagliptin is a recently approved dipeptidyl peptidase DPP
2024-04-03

Linagliptin is a recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor and widely considered as first-line treatment for patients with type 2 diabetes. DPP-4 is responsible for the inactivation of incretin hormones, such as glucagon-like peptide 1 (GLP-1). GLP-1 is released by the intestine aft
-
However relatively little information is
2024-04-03

However, relatively little information is available concerning the biochemical properties and other features of such enzymes in Taeniid species. In the current report, a M17 leucine aminopeptidase gene of T. pisiformis (TpLAP) was cloned and expressed, and its enzymatic activity, biochemical propert
-
br The lipoxygenase pathway in vascular physiology and
2024-04-03

The 12/15-lipoxygenase pathway in vascular physiology and pathology The mammalian 12- and 15-LOXs have high substrate specificity oxidizing predominantly ω−6 (arachidonic and linoleic acids) but also the ω−3 (docosahexanoic) c di gmp [86], [87], [88]. Different LOXs oxidize fatty acids both in th
-
Some of the earliest LOX
2024-04-03

Some of the earliest 12-LOX inhibitors were redox inhibitors, including nordihydroguaiaretic N-(p-amylcinnamoyl) receptor (NDGA), BW 755C, and baicalein 48, 49, 50. Redox inhibitors block the oxidation of the nonheme iron at the cataylytic site, preventing its conversion from the inactive (Fe2+) to
-
It has been largely demonstrated that several clinico pathol
2024-04-02

It has been largely demonstrated that several clinico-pathological factors influence ovarian cancer patients' prognosis, including residual tumor at primary cytoreductive surgery, FIGO stage, tumor grading, cancer histology and performance status [3,4]. Nevertheless, the recent awareness achieved in
-
Lipotoxicity is the accumulation of excess lipids
2024-04-02

Lipotoxicity is the accumulation of excess lipids in non-adipose tissues that leads to cell dysfunction or cell death. It may play an important role in the pathogenesis of diabetes, and contributes to the rate of progression of CKD [7,8]. Emerging evidence indicates that renal lipid dysregulation i
15639 records 172/1043 page Previous Next First page 上5页 171172173174175 下5页 Last page